Gibson, Danny
Branscombe, Neil
Martin, Neil
Menzies-Gow, Andrew
Jain, Priya
Padgett, Katherine
Yeates, Florian
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 11 August 2024
First Online: 28 August 2024
Declarations
:
: This work was supported by AstraZeneca, who provided research funding for this study.
: Danny Gibson, Neil Branscombe, Neil Martin, Andrew Menzies-Gow, Priya Jain are employees of AstraZeneca. Katherine Padgett and Florian Yeates are employees of Health Economics and Outcomes Research (HEOR) Ltd. HEOR Ltd received fees from AstraZeneca in relation to this study.
: Data are available upon request from the authors.
: This study was conducted on a modelled population and as such no ethical approval is required.
: Not applicable.
: Not applicable.
: The cost-effectiveness model was developed in Microsoft Excel<sup>®</sup> 365. Any additional information about model programming is available from the corresponding author upon request.
: DG, AMG, and KP conceptualised and designed this study. KP and FY were responsible for data analysis. All authors contributed to interpretation of the results, and preparation and review of the manuscript. All authors read and approved the final version of the manuscript.